Liraglutide, semaglutide and tirzepatide are incretin-based therapies currently approved by FDA for the management of obesity, while triple GIPR/GCGR/GLP-1R agonist retatrutide (LY3437943), the cagrilintide/semaglutide (CagriSema) 2.4 mg combination, high-dose oral semaglutide, and oral orforglipron are in advanced stages of development
In rare cases, allergic reactions may occur
The skin is designed to be a barrier, and many peptides are hydrophilic, meaning they dissolve in water rather than in the lipids that make up the skin barrier
The Short Answer (And Why It's Not So Simple) Let's get this out of the way immediately
Risks and Important Considerations While these supplements offer significant benefits, as a doctor, I must emphasize that they are not magic pills without risks
1,2,98 Pregnancy According to the EFSA, there is no evidence for teratogenicity or adverse effects on fertility or postnatal development with B12